Department of Interventional Radiology, Moscow Clinical Research Centre, Moscow, Russia.
Department of Hepato-Pancreato-Biliary Surgery, Moscow Clinical Research Centre, Moscow, Russia.
BJS Open. 2020 Feb;4(1):101-108. doi: 10.1002/bjs5.50225. Epub 2019 Oct 30.
Percutaneous radiofrequency-assisted liver partition with portal vein embolization in staged liver resection (PRALPPS) represents an alternative to portal vein embolization (PVE) followed by major liver resection in patients with perihilar cholangiocarcinoma.
This was an observational case-control study. Both procedures were applied in patients with a future liver remnant (FLR) volume of less than 40 per cent. The main end points of the study were short-term morbidity and mortality for the two procedures. The study also compared the efficacy of the preresection phases estimated by kinetic growth rate (KGR), time interval and degree of hypertrophy of the FLR.
The first phase (preresection) was completed in 11 and 18 patients, and the second phase (resection) in nine and 14 patients, in the PRALPPS and PVE groups respectively. Major morbidity after the first stage did not differ between the groups. There were no differences in blood loss, severe morbidity or liver failure rate after the second stage, with no deaths. The mean KGR of the FLR after the preresection phase for PRALPPS was 3·8 (0·6-9·8) per cent/day, and that after PVE was 1·8 (0-6·7) per cent/day (P = 0·037). The mean time interval for FLR hypertrophy in the PRALPPS and PVE groups was 15 (6-29) and 20 (8-35) days respectively (P = 0·039).
Short-term outcomes were similar for PRALPPS and PVE in terms of safety. Remnant hypertrophy was achieved more rapidly by PRALPPS.
经皮射频辅助肝分割联合门静脉栓塞分期肝切除术(PRALPPS)是一种替代门静脉栓塞(PVE)后行肝切除术的方法,适用于肝门部胆管癌患者。
这是一项观察性病例对照研究。两种方法均应用于未来肝体积(FLR)小于 40%的患者。研究的主要终点是两种方法的短期发病率和死亡率。该研究还比较了动力学生长率(KGR)、FLR 增生时间间隔和增生程度来估计术前阶段的疗效。
PRALPPS 组和 PVE 组的第一阶段(术前)分别有 11 例和 18 例患者完成,第二阶段(切除)分别有 9 例和 14 例患者完成。第一阶段后主要发病率在两组之间没有差异。第二阶段后两组间出血量、严重发病率或肝衰竭发生率无差异,且无死亡病例。PRALPPS 组术前阶段 FLR 的平均 KGR 为 3.8(0.6-9.8)%/天,PVE 组为 1.8(0-6.7)%/天(P=0.037)。PRALPPS 组和 PVE 组 FLR 增生的平均时间间隔分别为 15(6-29)天和 20(8-35)天(P=0.039)。
PRALPPS 和 PVE 在安全性方面的短期结果相似。PRALPPS 可更快地实现残肝增生。